Woodworth Emily

SVP Emily Woodworth sold 7,631 shares at blended $104.95 (2 sales totaling $800,896.51), reducing BSX holdings by 94.6%.

Emily Woodworth, SVP Global Controller and CAO at Boston Scientific, executed 2 separate sales totaling 7,631 shares for $800,896.51, executed on 2025-03-03 and 2025-03-04 at prices of $104.97 and $104.63. This represents a reduction of 94.6% in her BSX holdings, from 8,063 shares to 432 shares post-transaction. The sales occurred near the company's 52-week high of $106.18 (current price is $104.71, -1.4% from peak), within a backdrop of strong recent momentum: 90-day return of +15.7% and annual revenue growth of +17.6%. The company reports solid fundamentals with $4.2B in quarterly revenue and $468.0M in net income, though a P/E of 75.88 reflects a premium valuation. Woodworth's track record shows only 1 prior open-market sell across all tickers, limiting pattern inference. The minimal residual holding of 432 shares after this transaction underscores the substantial scale of the liquidation relative to her prior position.

BSX SVP Emily Woodworth sold 9,887 shares at $101.13 on 2025-02-28, reducing stake by 82.4% to 2.1K shares.

Emily Woodworth, SVP Global Controller and CAO at Boston Scientific, sold 9,887 shares for $999,872.31 at $101.13 on 2025-02-28, reducing her holdings from 12,001 to 2,114 shares (an 82.4% reduction in position size). The sale occurred when BSX was trading approximately 1.2% below its 52-week high of $106.18, near the upper end of the 52-week range. With only 1 prior open-market sell on her cross-ticker track record and no prior BSX-specific trades measurable at the 90-day mark, this transaction does not establish a pattern of timing accuracy. As a controller and principal accounting officer, transactions by this role merit standard monitoring, though the magnitude and concentration of the sale against her remaining 2.1K-share position warrants documentation of the underlying business rationale.